Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
In this phase Ib study, the combination of FAP-IL2v, an immune-cytokine developed to overcome the limitations of wild-type IL2, with the CPI pembrolizumab did not show meaningful antitumor activity in patients who had progressed on prior CPI therapy, suggesting that FAP-IL2v alone cannot overcome CPI resistance or unresponsiveness.
Authors
- Oliver Edgar Bechter (ORCID: https://orcid.org/0000-0003-0667-3284)
- Ana Arance (ORCID: https://orcid.org/0000-0003-2896-1957)
- Lev Demidov (ORCID: https://orcid.org/0000-0002-8562-6082)
- Nassim Sleiman (ORCID: https://orcid.org/0009-0004-5705-0786)
- Miguel F. Sanmamed (ORCID: https://orcid.org/0000-0002-7295-6074)
- Ainara Soria Rivas (ORCID: https://orcid.org/0000-0002-4673-8989)
- Nino Keshelava (ORCID: https://orcid.org/0009-0001-0978-3393)
- Stefan Evers (ORCID: https://orcid.org/0009-0001-3060-9429)
- А. А. Феденко (ORCID: https://orcid.org/0000-0003-4927-5585)
- David Dejardin (ORCID: https://orcid.org/0000-0001-8960-5345)
- Eva Muñoz‐Couselo (ORCID: https://orcid.org/0000-0001-7556-7608)
- Hans Prenen (ORCID: https://orcid.org/0000-0001-8802-7352)
- Jean‐Jacques Grob (ORCID: https://orcid.org/0000-0002-0667-153X)
- Christophe Boetsch (ORCID: https://orcid.org/0009-0005-8467-0339)
- Shahneen Kaur Sandhu (ORCID: https://orcid.org/0000-0002-8660-4475)
- Elizabeth I. Buchbinder (ORCID: https://orcid.org/0000-0002-7979-8953)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Anton Kraxner (ORCID: https://orcid.org/0009-0003-5831-8054)
- Jehad Charo (ORCID: https://orcid.org/0000-0002-5409-9160)
- Volker Teichgräber (ORCID: https://orcid.org/0009-0008-0526-6584)
- Anna Spreafico (ORCID: https://orcid.org/0000-0002-3034-3042)
- Mohammed Milhem (ORCID: https://orcid.org/0000-0003-4663-6824)
- Caroline Ardeshir (ORCID: https://orcid.org/0009-0004-9845-8307)
- Caroline Robert (ORCID: https://orcid.org/0000-0002-9493-0238)
- Mario Sznol (ORCID: https://orcid.org/0000-0003-4137-9662)
- Christin Habigt (ORCID: https://orcid.org/0009-0008-5806-7650)
- Nicole Alice Martin
Institutions
- Roche (Switzerland) (CH)
- Hebron University (PS)
- University of Iowa (US)
- The University of Sydney (AU)
- Beth Israel Deaconess Medical Center (US)
- The University of Melbourne (AU)
- Aix-Marseille Université (FR)
- Instituto Cajal (ES)
- Université Paris-Saclay (FR)
- Royal North Shore Hospital (AU)
- Universitair Ziekenhuis Leuven (BE)
- Peter MacCallum Cancer Centre (AU)
- Instituto de Salud Carlos III (ES)
- Institut Gustave Roussy (FR)
- University of Iowa Hospitals and Clinics (US)
- Princess Margaret Cancer Centre (CA)
- Yale University (US)
- University of New Haven (US)
- Russian Cancer Research Center NN Blokhin (RU)
- Roche Pharma AG (Germany) (DE)
- Antwerp University Hospital (BE)
- Roche (United Kingdom) (GB)
- Hospital Clínic de Barcelona (ES)
- Dana-Farber Cancer Institute (US)
- Melanoma Institute Australia (AU)
- Clinica Universidad de Navarra (ES)
- P.A. Hertzen Moscow Oncology Research Institute (RU)
- Iowa City Public Library (US)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Vall d'Hebron Institute of Oncology (ES)
- KU Leuven (BE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0601
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- F. Hoffmann-La Roche